Abstract
Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles and neuronal loss. Amyloid-β protein (Aβ) deposition plays a critical role in the development of AD. It is now generally accepted that massive neuronal death due to apoptosis is a common characteristic in the brains of patients suffering from neurodegenerative diseases, and apoptotic cell death has been found in neurons and glial cells in AD. Melatonin is a secretory product of the pineal gland; melatonin is a potent antioxidant and free radical scavenger and may play an important role in aging and AD. Melatonin decreases during aging and patients with AD have a more profound reduction of this indoleamine. Additionally, the antioxidant properties, the anti-amyloidogenic properties and anti-apoptotic properties of melatonin in AD models have been studied. In this article, we review the antiamyloidogenic and anti-apoptotic role of melatonin in AD.
Keywords: Alzheimer disease, neurodegeneration, neuroprotection, melatonin, amyloid beta-protein, amyloid precursor protein, apoptosis, mitochondria
Current Neuropharmacology
Title: Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Volume: 8 Issue: 3
Author(s): Hongwen He, Weiguo Dong and Fang Huang
Affiliation:
Keywords: Alzheimer disease, neurodegeneration, neuroprotection, melatonin, amyloid beta-protein, amyloid precursor protein, apoptosis, mitochondria
Abstract: Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles and neuronal loss. Amyloid-β protein (Aβ) deposition plays a critical role in the development of AD. It is now generally accepted that massive neuronal death due to apoptosis is a common characteristic in the brains of patients suffering from neurodegenerative diseases, and apoptotic cell death has been found in neurons and glial cells in AD. Melatonin is a secretory product of the pineal gland; melatonin is a potent antioxidant and free radical scavenger and may play an important role in aging and AD. Melatonin decreases during aging and patients with AD have a more profound reduction of this indoleamine. Additionally, the antioxidant properties, the anti-amyloidogenic properties and anti-apoptotic properties of melatonin in AD models have been studied. In this article, we review the antiamyloidogenic and anti-apoptotic role of melatonin in AD.
Export Options
About this article
Cite this article as:
He Hongwen, Dong Weiguo and Huang Fang, Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246137
DOI https://dx.doi.org/10.2174/157015910792246137 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trifluoroethanol-induced Activity and Structural Changes in Bos taurus Copper- and Zinc-containing Superoxide Dismutase
Protein & Peptide Letters Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders
Current Neuropharmacology One-pot Synthesis of Dihydropyrano[2,3-c]chromenes via a Three-component Reaction in Aqueous Media
Combinatorial Chemistry & High Throughput Screening White Matter Neuroprotection in Preterm Infants
Current Pediatric Reviews Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease
Current Medicinal Chemistry Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Metabolic Alterations in the Outer Membrane Vesicles of Patients with Alzheimer’s Disease: An LC-MS/MS-based Metabolomics Analysis
Current Alzheimer Research Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry A Novel Physico-Chemical Property Based Model for Studying the Effects of Mutation on the Aggregation of Peptides
Protein & Peptide Letters Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Oxidative Stress in Schizophrenia
Current Neuropharmacology Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued)